Fibriilide

Fibriilide, also known as felodipine, is a medication used to treat high blood pressure and coronary artery disease. It belongs to the class of dihydropyridine calcium channel blockers. The drug works by relaxing the muscles in the walls of arteries, allowing for improved blood flow and reducing blood pressure.

Fibriilide was first introduced in the 1980s and was initially approved for use in Europe. It has since gained approval in several countries around the world, including the United States, Canada, and Australia. The medication is available in various strengths and formulations, including immediate-release tablets and extended-release tablets.

Clinical indications for fibriilide include hypertension, angina, and coronary artery disease. It is often prescribed as a monotherapy or as part of a combination therapy with other medications. Fibriilide has been shown to be effective in reducing blood pressure and alleviating symptoms of coronary artery disease.

Side effects of fibriilide can include dizziness, headache, and swelling of the feet or ankles. Rare but serious side effects include hypotension and angioedema. Fibriilide can also interact with other medications, including beta blockers, and can increase the risk of hypotension and other adverse effects.

Fibriilide is metabolized by the liver and eliminated through the kidneys. The average half-life is 11-15 hours, and the medication is excreted mainly in the feces. The recommended dosing interval is 2-3 times a day, and the initiation of fibriilide therapy should be carefully monitored by a healthcare professional.